A new loop-mediated isothermal amplifi cation (LAMP) test kit, including a simple DNA extraction device for the detection of Mycobacterium tuberculosis complex, was developed for commercial use and evaluated for its usefulness in diagnosing tuberculosis (TB). D E S I G N : The LAMP test was performed using untreated and N-acetyl-L-cysteine (NALC) NaOH-treated sputum specimen. The effi ciency of the kit was compared with other conventional laboratory examinations, including other nucleic acid amplifi cation (NAA) tests. TUBERCULOSIS (TB) remains a major life-threatening disease. 1 Direct sputum smear microscopy is the main diagnostic tool for the detection of TB in many developing countries. However, the sensitivity of smear microscopy is relatively low, and this could be a major obstacle to the early diagnosis of TB. The human immunodefi ciency virus (HIV) pandemic further reduces its value due to the low yield of acid-fast bacilli (AFB) in sputum specimens from HIV-infected TB patients. [2] [3] [4] Nucleic acid amplifi cation (NAA) is a powerful diagnostic tool for the detection of TB, with high efficiency. It has been reported that the sensitivity and specifi city of NAA is almost equal to that of culture in smear-positive specimens. [5] [6] [7] [8] [9] [10] [11] Even in developing countries, NAA can deliver high performance in detecting the Mycobacterium tuberculosis complex (MTC). [12] [13] [14] Although NAA is widely utilised in many advanced countries, it is still not routinely applicable in developing countries due to its high cost, complicated procedures, insuffi cient laboratory facilities and shortage of skilled technologists. [15] [16] [17] Loop-mediated isothermal amplifi cation (LAMP, Eiken Chemical Co Ltd, Tokyo, Japan) is a simple NAA method that does not require expensive devices or detection systems. [18] [19] [20] Boehme et al. recently reported that the LAMP method showed 97.7% sensitivity with smear-positive sputum specimens, and 48.8% with smear-negative, culture-positive specimens, with a short amplifi cation time. 21 Eiken Chemical has modifi ed the kit used in that study, and has developed a new simple, contamination-resistant kit for the diagnosis of TB. This new LAMP kit was evaluated to diagnose TB in the present study.
TUBERCULOSIS (TB) remains a major life-threatening disease. 1 Direct sputum smear microscopy is the main diagnostic tool for the detection of TB in many developing countries. However, the sensitivity of smear microscopy is relatively low, and this could be a major obstacle to the early diagnosis of TB. The human immunodefi ciency virus (HIV) pandemic further reduces its value due to the low yield of acid-fast bacilli (AFB) in sputum specimens from HIV-infected TB patients. [2] [3] [4] Nucleic acid amplifi cation (NAA) is a powerful diagnostic tool for the detection of TB, with high efficiency. It has been reported that the sensitivity and specifi city of NAA is almost equal to that of culture in smear-positive specimens. [5] [6] [7] [8] [9] [10] [11] Even in developing countries, NAA can deliver high performance in detecting the Mycobacterium tuberculosis complex (MTC). [12] [13] [14] Although NAA is widely utilised in many advanced countries, it is still not routinely applicable in developing countries due to its high cost, complicated procedures, insuffi cient laboratory facilities and shortage of skilled technologists. [15] [16] [17] Loop-mediated isothermal amplifi cation (LAMP, Eiken Chemical Co Ltd, Tokyo, Japan) is a simple NAA method that does not require expensive devices or detection systems. [18] [19] [20] Boehme et al. recently reported that the LAMP method showed 97.7% sensitivity with smear-positive sputum specimens, and 48.8% with smear-negative, culture-positive specimens, with a short amplifi cation time. 21 Eiken Chemical has modifi ed the kit used in that study, and has developed a new simple, contamination-resistant kit for the diagnosis of TB. This new LAMP kit was evaluated to diagnose TB in the present study.
MATERIALS AND METHODS

Patients and clinical specimens
This study was conducted at the Double-Barred Cross Hospital and Tokyo Hospital in Japan. All participants were suspected to be positive for TB, with typical symptoms and/or chest X-ray fi ndings. A total of 170 patients (TB and non-TB) were enrolled in the study. The patients (TB suspects) were asked to submit two sputum specimens (at least 2 ml) on two consecutive mornings; 340 sputum specimens were collected from June to December 2009. Patients were fi nally diagnosed based on bacteriological, histopathological and/or clinical fi ndings, such as clinical improvement after anti-tuberculosis chemotherapy. Mycobacterium spp. other than M. tuberculosis (MOTT) infections were diagnosed using Japanese Anti-Tuberculosis Association criteria. 22 The present study was approved by the Ethics Committee of both hospitals. Subjects were enrolled after obtaining written informed consent. Subjects aged <18 years, and those who had been receiving anti-tuberculosis treatment for >48 h, including fl uoroquinolones and aminoglycosides 60 days prior to enrolment, were excluded.
AFB smear and culture
Morning sputum specimens were collected from the patients. The quality of each specimen was recorded using the criteria of Miller and Jones. 23 Untreated sputum specimens were divided equally into two tubes; one specimen was treated using the standard Nacetyl-L-cysteine (NALC) NaOH digestion method, followed by neutralisation with phosphate buffer (PB; pH 6.8) and centrifugation at 3000 g for 15 min at 4°C. The sediment was re-suspended in 2 ml of PB, and one part was submitted for auramine-O fl uorescent smear microscopy. The same re-suspended specimen was cultured with BACTEC Mycobacterial Growth Indicator Tube (MGIT) 960 (Nippon Becton Dickinson Co Ltd, Tokyo, Japan) and 2% Ogawa medium (Kyokuto Pharmaceuticals, Tokyo, Japan) at 37°C for up to 6 and 8 weeks, respectively. All positive cultures were subjected to identifi cation with immunochromatographic (CapiliaTB; TAUNS, Shizuoka, Japan) methods. If MOTT were isolated, identifi cation tests were performed using nucleic acid probes (DDH mycobacterium 'Kyokuto'; Kyokuto Pharmaceuticals, Japan).
One part of the re-suspended sediment was subjected to the LAMP test and Cobas Amplicor MTB (Roche Diagnostics Systems Inc, Tokyo, Japan) or TRC Rapid MTB (Tosoh Co, Tokyo, Japan) for the detection of MTC. If the NAA tests were not performed immediately, the treated specimen was stored at −20°C until use. Another raw sputum specimen was subjected to direct fl uorescent smear microscopy and the LAMP test using approximately 40 μl of the purulent part. The whole process was repeated for the second specimen.
LAMP and other NAAs
A commercial version of the LAMP kit for TB detection was used in the study. The kit was provided by Eiken Chemical and was composed of a DNA extraction device and LAMP reaction tube. Approximately 40 μl of untreated/treated sputum specimen was mixed with the DNA extraction solution (960 μl) by inversion in a proprietary tube (heating tube) and incubated at 90°C for 5 min using a proprietary heat block. After incubation, the DNA was purifi ed through porous material in a closed system (adsorbent tube) called PURE (Procedure for Ultra Rapid Extraction, Eiken Chemical). The extracted DNA in 30 μl of solution was directly added to the LAMP reaction tube containing dried LAMP reaction mix (primers, dNTPs, buffer and Bst DNA polymerase). The primers used in this kit were modifi ed from those previously reported, 21 and had high species specifi city for MTC (internal data). The LAMP reaction tube was mixed by inversion (fi ve times) and incubated at 67°C for 40 min (Figure) . A positive LAMP result was detected by real-time measurement of turbidity and visually using fl uorescence under ultra-violet light. The LAMP test was also performed using NALCNaOH treated specimens.
Cobas Amplicor MTB or TRC Rapid MTB were performed according to the manufacturer's instructions using respectively 100 and 200 μl of treated sputum specimen. A fi nal volume of respectively 25 and 20 μl was used for each reaction. Tokyo Hospital used TRC Rapid MTB for the fi rst specimen only due to capacity limitations.
Statistical analysis
Analyses were conducted on the sensitivity and specifi city of the LAMP test for active TB compared to other NAA tests; the difference in these parameters was tested using the χ 2 method. A linear regression analysis with smear positivity was also performed. Statistical analysis was performed using JMP 6.0.3 (SAS Institute, Cary, NC, USA). P < 0.05 was considered statistically signifi cant.
RESULTS
Patient diagnosis
A total of 10 patients suspected of having TB were excluded, as one patient died on the fi rst day and the remaining nine did not conform to the enrolment criteria. The fi nal analyses were performed for 320 specimens from 160 patients. No specimen was excluded from the analyses. A total of 127 patients were diagnosed with active TB, and 18 had MOTT infections. Among the 127 active TB patients, 119 were MTC culture-positive, while the remaining eight were culture-negative. Three culture-negative TB cases were smear-positive and all were NAA-positive, while fi ve were negative for all bacterial examinations, but were diagnosed using chest X-ray fi ndings and antituberculosis treatment response. Non-mycobacterial diseases were found in 15 patients: bronchiectasis with bacterial infection (n = 3), bacterial pneumonia (n = 3), old TB (n = 2), lung cancer (n = 2), bronchial asthma (n = 2), sarcoidosis (n = 1), pulmonary aspergillosis (n = 1) and lung abscess (n = 1).
AFB smear and culture
Among 320 sputum samples from 160 TB suspects, respectively 188 (58.8%) and 201 (62.8%) specimens were direct and indirect (concentrated) smear-positive. The quality of 179 (55.6%) of the 320 sputum specimens was M1 or M2, while 66 (20.6%) were P3.* A total of 115 (71.9%) suspects were smear-positive and 45 (28.1%) were negative. Of 254 sputum specimens from active TB cases, respectively 176 (69.3%) and 188 (74.0%) were positive for direct and indirect smear examination.
Solid cultures were positive for 214 (66.9%) specimens, while MGIT cultures were positive for 236 (73.8%) specimens. The majority of the positive specimens were due to MTC (223 isolates in total), while 16 isolates were M. avium or M. intracellulare, four isolates were M. kansasii and one isolate was M. xenopi. Mixed infection (MTC and MOTT) was detected in two specimens.
LAMP vs. other NAAs
The results of LAMP using untreated (raw: direct) and treated (digested and concentrated: indirect) sputum specimens are summarised in Table 1 . A result was considered positive if either direct or indirect smear examination of the specimen was positive. Sensitivity was calculated using the culture result as the gold standard. As described above, some MOTTs were isolated by culture; they were, however, classifi ed in the culture MTC-negative group. Cases of mixed infection with MTC and MOTT were considered to be culture MTC-positive and TB-positive. Table 2 shows the total sensitivity and specifi city of diagnosing a person with TB with two sputum specimens. There was no signifi cant difference in specifi city between LAMP and other NAAs. Instances with positive direct LAMP and negative Cobas Amplicor MTB were seen in fi ve patients with TB and two with NTM. Positive direct LAMP and negative TRC Rapid MTB were seen in four TB and one NTM patient. Amplicor MTB-positive but LAMP (direct or indirect) negative results were observed in 19 patients. Two false-positive results of direct LAMP were obtained from the patient with aspergillosis. The results were not considered to be bacteriologically false due to previous history and pulmonary TB sequelae. It was speculated that the LAMP test could detect DNA from non-active MTC. Cobas Amplicor MTB was false-positive for two specimens from a patient with pulmonary pneumonia and M. kansasii infection. TRC Rapid MTB was positive for one specimen collected from a patient with bronchiectasis. These could be due to laboratory or bedside cross-contamination. The sensitivity and specifi city of the direct LAMP method was comparable with other NAA methods, while the sensitivity of indirect LAMP was slightly lower. Comparisons of the positive and negative likelihood ratios were also similar.
The relationship between the degree of smear positivity of sputum specimens and their NAA test results in terms of positive rates is shown in Table 3 according to the methods used. For simplicity, a linear regression analysis with the positive rate as a subordinate variable and the degree of positivity as an independent variable (as negative = 1, scanty = 2, 1+ = 3, 2+ = 4, 3+ = 5) was performed. According to the χ 2 test for trend, the slope and linearity for all four methods were signifi cant.
DISCUSSION
Due to the HIV epidemic and the emergence of drugresistant TB, 24 a laboratory test with a short turnaround time (TAT) and high sensitivity is urgently needed. 25 In general, liquid culture shows the highest sensitivity, 26,27 but it is not easy to set up a culture laboratory for this purpose, mainly due to cost and bio-safety issues. 28, 29 The simple NAA method is therefore the most promising for application even in peripheral laboratories, particularly in developing countries. LAMP is an NAA method that can be performed in one tube under isothermal conditions, and has high amplifi cation effi ciency. It has already been demonstrated that the in-house LAMP method has a sensitivity similar to that of culture for the detection of MTC from clinical specimens. [30] [31] [32] The sensitivity of direct LAMP (88.2%) was somewhat lower than Cobas Amplicor MTB and TRC Rapid MTB; however, the difference was not statistically signifi cant. The sensitivities of direct and indirect smear microscopy for diagnosing TB in this study were respectively 69.3% (176/254) and 74.0% (188/254). The sensitivity of the direct LAMP method was higher than direct smear microscopy (P = 0.006), but that of indirect LAMP did not exceed indirect smear microscopy. With a positivity rate in smearpositive cases of nearly 100%, and that in smearnegative, culture-positive cases well over 50%, the LAMP test is considered to have a sensitivity intermediate between the smear and culture examination methods, and its performance is roughly similar to that of other tested NAAs, except for indirect LAMP for smear-negative specimens.
There are several other NAAs already in practical use, such as BD ProbeTec ET (BD, USA), GenoType Mycobacteria Direct (HAIN Lifescience, Nehren, Germany) and Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA). The sensitivity of BD ProbeTec ET for the detection of MTC has been reported as respectively 96.7-100% and 12.5-66.0% for smear-positive and -negative specimens. [33] [34] [35] The sensitivity of GenoType Mycobacteria Direct for the detection of MTC has also been reported as 97.9-98.7% and 80.0-89.6% for smear-positive and -negative specimens. 36, 37 Boehme et al. recently reported a sensitivity of the Xpert MTB/RIF (Cepheid) test of 72.5% for smear-negative, culture-positive specimens. The sensitivity of the direct LAMP test was in line with other NAAs for smearpositive specimens, but was lower for smear-negative specimens. 38 Although direct comparisons still need to be carried out, the present results suggest limitations of the new LAMP test kit and the importance of culture examination for optimal detection of MTC.
The present study indicated signifi cantly lower sensitivity of the indirect LAMP test for smear-negative specimens compared with other NAAs. One possible reason for the low sensitivity of the commercial version of the LAMP test is the small volume of specimen used in the reaction. The Cobas Amplicor MTB uses 100 μl of treated sputum, and approximately 25% of the extracted nucleic acids (v/v) are employed for the amplifi cation. Similarly, TRC Rapid MTB starts from 200 μl, and uses approximately 10%. The LAMP method starts with only 40 μl of sputum and the fi nal volume used for amplifi cation is 1.2 μl, which corresponds to approximately 3% of the original specimen as nucleic acids. The relatively lower positivity rate of LAMP compared with other NAAs could be due to the smaller amount of target nucleic acids used in the reaction. The addition of NALC to the specimen was the only difference in the procedure for indirect LAMP compared to direct LAMP. We compared the effect of NALC on LAMP using several sputum specimens, and concluded that this treatment had no effect on the outcome of the test (data not shown). It is conceivable that the centrifugation and homogenisation steps in the indirect test could reduce the concentration of AFB in the specimens, causing differences in the results between the direct and indirect methods. Another possibility is that the laboratory technologists carefully selected the purulent part of the sputum specimens for the test, thus achieving the higher positivity, especially in paucibacillary specimens. Amplifi cation inhibition is a common cause of falsenegatives. However, as discrepant results between NAAs occurred mainly with smear-negative samples (Table 3) , we concluded that there was little possibility of inhibition.
The population in this study had special features, with a high percentage of active TB cases (79.4%) and some with pulmonary diseases other than active TB, including MOTTs. We documented LAMP performance separately for specimens graded for bacillary load in terms of smear positivity. The performance of LAMP tests remains similar to that of other NAAs, in terms both of sensitivity in smear-negative, culture-positive specimens, and of similarity in the dose-response relationship. It was thus considered that LAMP and other NAAs were fairly evaluated in this study.
As a practical problem, cross-contamination and complicated procedures are major obstacles to the routine use of NAA. The prototype LAMP kit requires nucleic acid extraction, centrifugation, two washes with a buffer, amplifi cation and detection. The new LAMP kit requires neither centrifugation nor target purifi cation by washing with buffer. A further advantage of the new kit is the reduced number of steps, which results in a lower risk of cross-contamination. The amplifi ed product is not removed from the reaction tube, and is disposed of directly without opening the tube. Another advantage is the short hands-on time. The average time required for one test is approximately 1 h, and one additional specimen adds only a few minutes for mixing with extraction reagent and dropping the extracted DNA into the tube. Thus, for example, the time for testing six specimens, including negative and positive controls, will be only 1.5 h.
CONCLUSION
A new commercial version of the LAMP kit was evaluated using clinical specimens for the diagnosis of TB. The new LAMP kit is very simple, rapid and easy to use. The overall performance of the LAMP test was intermediate between the smear and culture methods. This implies that the LAMP test will detect approximately half of smear-negative, culture-positive TB cases, which seems slightly less than other NAAs. The specifi city of diagnosing TB among those suspected of having the disease will be essentially 100%, provided laboratory quality is maintained. It will be useful as a primary testing tool for TB, and may provide additional diagnostic value (sensitivity and species specifi city) to complement smear examination by microscopy in many health care settings.
